On the stock market since 2017, it operates in the world of health and science. It has 45 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $35.1M a year. A small number, but proof the product has real buyers.
There is $253.0M in the vault; even if every debt were paid off, $175.7M would remain.
Over the last 12 months, company executives reported 9 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $79.2M against $35.1M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 19/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 24/100.
On our five-subject report card, XFOR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: XFOR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (24/100) says the stock isn’t cheap.